Iovance Alliance: LN-145 Across Multiple Tumor Types
Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Researchers at the University of Texas MD Anderson Cancer Center are recruiting patients with recurrent neoplasms of bone and articular cartilage or female genital organs to trial a combination treatment of routine chemotherapy and tumor-infiltrating lymphocytes (TILs) from the patient’s own body, collected and multiplied in the lab to magnify their ability to infiltrate and battle tumors.
The treatment will involve extraction of TILs from the patient’s tumor, then lab processing will amplify their numbers and optimize their anti-tumor potential. After a chemotherapy course, the TILs will be infused along with a pro-drug to help their growth. Observation and questionnaires will be required for the first 12 weeks, then follow up continues for ~2 years.
- Be 16 to 70 years of age
- Meet cancer screening requirements specific to the study
- Not be pregnant or breastfeeding, be willing to use contraception for the study period
- Not have active viral hepatitis
THE STUDY INVOLVES:
- Screening before the treatment.
- A course of chemotherapy prior to first Tetanus/Diptheria booster.
- Vaccine injections under the skin 22-24 days after step (2), then at 2 week intervals with recurring cycles of chemo until their disease shows progression or they experience toxicity.
- Monitoring of the patient during treatment, then follow up via lab and physical assessments for ~2 years.
LOCATIONS AND CONTACTS:
University of Texas MD Anderson Cancer Center in Houston, TX is recruiting participants for this study. Map
Contact: Ljiljana Milojevic | 713-792-8578 | [email protected]
Contact: Virginia A Bayer, RN | 713-563-3877 | [email protected]
University of Florida
National Cancer Institute (NCI)
Or go online: